Atsunori Fukuhara

Dr. Atsunori Fukuhara

orcid

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2007 in Diabetes
Verified
Journal Article
Open access
PDF file
NHNaomi Hosogai
Naomi Hosogai
AFAtsunori Fukuhara
Atsunori Fukuhara
KOKazuya Oshima
Kazuya Oshima
YMYugo Miyata
Yugo Miyata
STSachiyo Tanaka
Sachiyo Tanaka
ISIichiro Shimomura
Iichiro Shimomura
Obesity is linked to a variety of metabolic disorders, such as insulin resistance and atherosclerosis. Dysregulated production of fat-derived secretory factors, adipocytokines, is partly responsible for obesity-linked metabolic disorders. However, the mechanistic role of obesity per se to adipocytokine dysregulation has not been fully elucidated. Here, we show that adipose tissue of obese mice is hypoxic and that local adipose tissue hypoxia dysregulates the production of adipocytokines. Tissue hypoxia was confirmed by an exogenous marker, pimonidazole, and by an elevated concentration of lactate, an endogenous marker. Moreover, local tissue hypoperfusion (measured by colored microspheres) was confirmed in adipose tissue of obese mice. Adiponectin mRNA expression was decreased, and mRNA of C/EBP homologous protein (CHOP), an endoplasmic reticulum (ER) stress–mediated protein, was significantly increased in adipose tissue of obese mice. In 3T3-L1 adipocytes, hypoxia dysregulated the expression of adipocytokines, such as adiponectin and plasminogen activator inhibitor type-1, and increased the mRNAs of ER stress marker genes, CHOP and GRP78 (glucose-regulated protein, 78 kD). Expression of CHOP attenuated adiponectin promoter activity, and RNA interference of CHOP partly reversed hypoxia-induced suppression of adiponectin mRNA expression in adipocytes. Hypoxia also increased instability of adiponectin mRNA. Our results suggest that hypoperfusion and hypoxia in adipose tissues underlie the dysregulated production of adipocytokines and metabolic syndrome in obesity.

1 June 2005 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
KOKazuya Oshima
Kazuya Oshima
ANAkihide Nampei
Akihide Nampei
MMMorihiro Matsuda
Morihiro Matsuda
MIMasanori Iwaki
Masanori Iwaki
AFAtsunori Fukuhara
Atsunori Fukuhara
ISIichiro Shimomura
Iichiro Shimomura

1 July 2004 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
TOTakako Ooshio
Takako Ooshio
KIKenji Irie
Kenji Irie
KMKoji Morimoto
Koji Morimoto
AFAtsunori Fukuhara
Atsunori Fukuhara
TIToshio Imai
Toshio Imai
YTYoshimi Takai
Yoshimi Takai
Nectins are Ca2+-independent immunoglobulin-like cell-cell adhesion molecules that are involved in formation of cadherin-based adherens junctions (AJs). The nectin-based cell-cell adhesion induces activation of Cdc42 and Rac small G proteins, which eventually enhances the formation of AJs through reorganization of the actin cytoskeleton. Although evidence has accumulated that nectins recruit cadherins to the nectin-based cell-cell adhesion sites through their cytoplasm-associated proteins, afadin and catenins, it is not fully understood how nectins are physically associated with cadherins. Here we identified a rat counterpart of the human LIM domain only 7 (LMO7) as an afadin- and α-actinin-binding protein. Rat LMO7 has two splice variants, LMO7a and LMO7b, consisting of 1,729 and 1,395 amino acids, respectively. LMO7 has calponin homology, PDZ, and LIM domains. Western blotting revealed that LMO7 was expressed ubiquitously in various rat tissues. Immunofluorescence and immunoelectron microscopy revealed that LMO7 localized at cell-cell AJs, where afadin localized, in epithelial cells of rat gallbladder. In addition, LMO7 localized at the cytoplasmic faces of apical membranes in the same epithelial cells. We furthermore revealed that LMO7 bound α-actinin, an actin filament-bundling protein, which bound to α-catenin. Immunoprecipitation analysis revealed that LMO7 was associated with both the nectin-afadin and E-cadherin-catenin systems. LMO7 was assembled at the cell-cell adhesion sites after both the nectin-afadin and E-cadherin-catenin systems had been assembled. These results indicate that LMO7 is an afadin- and α-actinin-binding protein that connects the nectin-afadin and E-cadherin-catenin systems through α-actinin.

6 July 1999 in Circulation
Verified
Journal Article
Closed access
PDF file
ETEtsuo Tsuchikane
Etsuo Tsuchikane
AFAtsunori Fukuhara
Atsunori Fukuhara
TKTohru Kobayashi
Tohru Kobayashi
MKMotohiro Kirino
Motohiro Kirino
KYKeita Yamasaki
Keita Yamasaki
NANobuhisa Awata
Nobuhisa Awata
Background —Restenosis after percutaneous transluminal coronary (balloon) angioplasty (PTCA) remains a major drawback of the procedure. We previously reported that cilostazol, a platelet aggregation inhibitor, inhibited intimal proliferation after directional coronary atherectomy and reduced the restenosis rate in humans. The present study aimed to determine the effect of cilostazol on restenosis after PTCA. Methods and Results —Two hundred eleven patients with 273 lesions who underwent successful PTCA were randomly assigned to the cilostazol (200 mg/d) group or the aspirin (250 mg/d) control group. Administration of cilostazol was initiated immediately after PTCA and continued for 3 months of follow-up. Quantitative coronary angiography was performed before PTCA and after PTCA and at follow-up. Reference diameter, minimal lumen diameter, and percent diameter stenosis (DS) were measured by quantitative coronary angiography. Angiographic restenosis was defined as DS at follow-up >50%. Eligible follow-up angiography was performed in 94 patients with 123 lesions in the cilostazol group and in 99 patients with 129 lesions in the control group. The baseline characteristics and results of PTCA showed no significant difference between the 2 groups. However, minimal lumen diameter at follow-up was significantly larger (1.65±0.55 vs 1.37±0.58 mm; P <0.0001) and DS was significantly lower (34.1±17.8% vs 45.6±19.3%; P <0.0001) in the cilostazol group. Restenosis and target lesion revascularization rates were also significantly lower in the cilostazol group (17.9% vs 39.5%; P <0.001 and 11.4% vs 28.7%; P <0.001). Conclusions —Cilostazol significantly reduces restenosis and target lesion revascularization rates after successful PTCA.

4 April 2018 in Diabetes
Verified
Journal Article
Closed access
PDF file
YOYosuke Okuno
Yosuke Okuno
AFAtsunori Fukuhara
Atsunori Fukuhara
EHErika Hashimoto
Erika Hashimoto
HKHironori Kobayashi
Hironori Kobayashi
SKSachiko Kobayashi
Sachiko Kobayashi
ISIichiro Shimomura
Iichiro Shimomura
Recent studies have emphasized the association of adipose oxidative stress (Fat reactive oxygen species [ROS]) with the pathogenesis of metabolic disorders in obesity. However, the causal roles of Fat ROS in metabolic disturbances in vivo remain unclear because no mouse model has been available in which oxidative stress is manipulated by targeting adipocytes. In this research, we generated two models of Fat ROS–manipulated mice and evaluated the metabolic features in diet-induced obesity. Fat ROS–eliminated mice, in which Cat and Sod1 were overexpressed in adipocytes, exhibited adipose expansion with decreased ectopic lipid accumulation and improved insulin sensitivity. Conversely, Fat ROS–augmented mice, in which glutathione was depleted specifically in adipocytes, exhibited restricted adipose expansion associated with increased ectopic lipid accumulation and deteriorated insulin sensitivity. In the white adipose tissues of these mice, macrophage polarization, tissue fibrosis, and de novo lipogenesis were significantly changed. In vitro approaches identified KDM1A-mediated attenuation of sterol-regulatory element-binding transcription factor 1 (SREBF1) transcriptional activities as the underlying mechanism for the suppression of de novo lipogenesis by oxidative stress. Thus, our study uncovered the novel roles of Fat ROS in healthy adipose expansion, ectopic lipid accumulation, and insulin resistance, providing the possibility for the adipocyte-targeting antioxidant therapy.

25 October 2002 in Oncogene
Verified
Journal Article
Closed access
PDF file
AFAtsunori Fukuhara
Atsunori Fukuhara
KIKenji Irie
Kenji Irie
HNHiroyuki Nakanishi
Hiroyuki Nakanishi
KTKyoji Takekuni
Kyoji Takekuni
TKTomomi Kawakatsu
Tomomi Kawakatsu
YTYoshimi Takai
Yoshimi Takai